-
甲状腺癌是内分泌系统最常见的恶性肿瘤,也是近二十多年发病率增长最快的实体癌,且主要为甲状腺乳头状癌(papillary thyroid carcinoma,PTC)。鼠类肉瘤滤过性毒菌致癌基因同源体B1(v-raf murine sarcoma viral oncogene homolog B1,BRAF)基因突变是PTC最常见的基因变化,目前认为PTC的发生、发展主要与BRAF基因突变密切相关[1],PTC患者BRAF基因突变的临床意义越来越受到关注。对于BRAF基因作为PTC术前的辅助诊断、手术方式的指导、初始危险度分层和术后选择放射性碘治疗等的分子标志物的意见仍不统一,本文就相关问题综述如下。
BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展
Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer
-
摘要: 鼠类肉瘤滤过性毒菌致癌基因同源体B1(BRAF)基因突变是甲状腺乳头状癌(PTC)最常见的基因变化。相关性分析显示PTC的发生、发展与BRAF基因突变密切相关,BRAF基因突变对PTC的诊断及治疗指导的价值受到了广泛关注。但现有的临床证据显示,不能单纯依赖BRAF基因突变制定PTC患者的手术方式、指导初始危险度分层及术后选择放射性碘治疗。索拉非尼和司美替尼可改善放射性碘抵抗性PTC患者的预后,但其疗效与患者BRAF基因突变与否无显著相关性。Abstract: v-raf murine sarcoma viral oncogene homolog B1(BRAF) mutation represents the most common oncogenic event in papillary thyroid cancer(PTC). The value of BRAF mutation in the diagnosis and guiding treatment of PTC has achieved enthusiastic investigation since the initiation and progression of PTC has been correlated with BRAF mutation. However, existing evidence does not suggest BRAF mutation as an independent factor in guiding surgical approach, stratifying recurrence risk, or selecting postoperative radioiodine therapy for PTC patients. Although sorafenib and selumetinib have effectively improved the prognosis of patients with radioactive iodine-refractory PTC, such efficacy is independent of BRAF mutation status
-
Key words:
- Thyroid neoplasms /
- Diagnosis /
- Therapy /
- BRAF mutation
-
[1] Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer:a functional Link to drive cancer progression[J]. Cancer Res, 2011, 71(7):2417-2422. [2] Capper D, Preusser M, Habel A, et al. Assessment of BRAFV600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody[J]. Acta Neuropathol, 2011, 122(1):11-19. doi: 10.1007/s00401-011-0841-z [3] 刘斌, 匡安仁. MAPK/ERK和PI3K/Akt信号通道的基因变异与甲状腺癌的发生发展及诊治[J].生物医学工程学杂志, 2012, 29(6):1221-1225.
[4] Xing M. BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762. doi: 10.1210/er.2007-0007 [5] Danilovic DL, Lima EU, Domingues RB, et al. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma[J]. Eur J Endocrinol, 2014, 170(4):619-625. [6] Rivkees SA, Mazzaferri EL, Verburg FA, et al. The treatment of differentiated thyroid cancer in children:emphasis on surgical approach and radioactive Iodine therapy[J]. Endocr Rev, 2011, 32(6):798-826. [7] Cañadas-Garre M, Becerra-Massare P, López de la Torre-Casares DM, et al. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens:a prospective study of 814 thyroid FNAB patients[J]. Ann Surg, 2012, 255(5):986-992. doi: 10.1097/SLA.0b013e31824e8d70 [8] Albarel F, Conte-Devolx B, Oliver C. From nodule to differentiated thyroid carcinoma:Contributions of molecular analysis in 2012[J]. Ann Endocrinol(Paris), 2012, 73(3):155-164. doi: 10.1016/j.ando.2012.03.002 [9] Dujardin F, Pagès JC, Collin C, et al. BRAF V600E mutation in papillary thyroid carcinoma:prevalence and detection in fine needle aspiration specimens[J]. Ann Pathol, 2010, 30(4):252-262. [10] Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma:pathogenic role and clinical implications[J]. J Chin Med Assoc, 2010, 73(3):113-128. doi: 10.1016/S1726-4901(10)70025-3 [11] Lee JW, Koo BS. The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer[J]. Gland Surg, 2013, 2(4):206-211. [12] Pelizzo MR, Dobrinja C, Casal IE, et al. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma[J]. Biomed Pharmacother, 2014, 68(4):413-417. doi: 10.1016/j.biopha.2014.03.008 [13] Yang K, Wang H, Liang ZY, et al. BRAFV600E mutation associated with Non-Radioiodine-Avid status in distant metastatic papillary thyroid carcinoma[J]. Clin Nucl Med, 2014, 39(8):675-679. doi: 10.1097/RLU.0000000000000498 [14] American Thyroid Association(ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214. doi: 10.1089/thy.2009.0110 [15] 中华医学会内分泌分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志, 2013, 33(2):96-115. doi: 10.3760/cma.j.issn.2095-2848.2013.02.003
[16] Walczyk A, Kowalska A, Kowalik A, et al. The BRAFV600E mutation in papillary thyroid microcarcinoma:does the mutation have an impact on clinical outcome?[J]. Clin Endocrinol(Oxf), 2014, 80(6):899-904. doi: 10.1111/cen.12386 [17] Xing MZ, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013, 309(14):1493-1501. doi: 10.1001/jama.2013.3190 [18] Schweppe RE, Kerege AA, Sharma VA, et al. Distinct genetic alterations in the Mitogen-Activated protein kinase pathway dictate sensitivity of thyroid cancer cells to Mitogen-Activated protein kinase kinase 1/2 inhibition[J]. Thyroid, 2009, 19(8):825-835. doi: 10.1089/thy.2008.0362 [19] Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation[J]. Cancer Res, 2005, 65(10):4238-4245. doi: 10.1158/0008-5472.CAN-05-0047 [20] Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways[J]. J Clin Endocrinol Metab, 2010, 95(2):820-828. doi: 10.1210/jc.2009-1888 [21] Haraldsdottir S, Shah MH. New era for treatment in differentiated thyroid cancer[J]. Lancet, 2014, 384(9940):286-288. doi: 10.1016/S0140-6736(14)60663-2 [22] Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib(AZD6244; ARRY-142886)in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements[J]. Clin Cancer Res, 2012, 18(7):2056-2065. doi: 10.1158/1078-0432.CCR-11-0563 [23] Brose MS, Nutting CM, Jarzab BA, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940):319-328. doi: 10.1016/S0140-6736(14)60421-9 [24] Fallahi P, Ferrari SM, Mazzi V, et al. Personalization of targeted therapy in advanced thyroid cancer[J]. Curr Genomics, 2014, 15(3):190-202. doi: 10.2174/1389202915999140404101902
计量
- 文章访问数: 3842
- HTML全文浏览量: 2750
- PDF下载量: 5